Erratum

Erratum on “Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective”

M.A. Salvino\textsuperscript{a,b}, C. Bonfim\textsuperscript{c}, R.T. Calado\textsuperscript{d}, H. Kim\textsuperscript{e}, J.F. Bertinato\textsuperscript{e}, P. Scheinberg\textsuperscript{f}

\textsuperscript{a} Hospital Universitário Professor Edgar Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil
\textsuperscript{b} Hospital São Rafael, Instituto D’Or de Ensino e Pesquisa (IDOR), Salvador, BA, Brazil
\textsuperscript{c} Blood and Marrow Transplantation Unit, Department of Hematology, Hospital de Clínicas da Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil
\textsuperscript{d} Department of Medical Imaging, Haematology, and Clinical Oncology, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
\textsuperscript{e} Novartis Biocências S.A., São Paulo, SP, Brazil
\textsuperscript{f} Division of Hematology, A Beneficência Portuguesa de São Paulo (BP), São Paulo, SP, Brazil

A R T I C L E   I N F O

Article history:
Available online 12 April 2022


Where it reads:

“This resulted in an incremental cost of R$ 116,268 per patient treated with IST alone.”

It should read:

“However, the combination saved resources related to HSCT, relapse and end of life. This resulted in an incremental cost of R$ 96,002 per patient treated with IST alone.”

Where it reads:

“resulting in an ICER of R$ 83,412 per life-year gained.”

it should read:

“resulting in an ICER of R$ 68,872 per life-year gained.”

http://dx.doi.org/10.1016/j.htct.2021.10.063

https://doi.org/10.1016/j.htct.2022.04.001

2531-1379/© 2022 Published by Elsevier Espana, S.L. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.